ORBERA INTRAGASTRIC BALLOON
BOSTON SCIENTIFIC CORPORATION · Decision date Jan 5, 2026
What did the FDA approve?
FDA records P140008/S028 as a supplement to PMA P140008, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jan 5, 2026.
FDA approval order statement
a manufacturing site change to replace the Apollo Endosurgery Coyol, Costa Rica facility with the Boston Scientific Coyol, Costa Rica facility for the Orbera Intragastric Balloon, following acquisition of Apollo Endosurgery by Boston Scientific
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Jan 5, 2026
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P140008/S028
- Regulatory pathway
- PMA supplement
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- LTI
- Decision code
- APPR
- Decision date
- Jan 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY.
- Applicant
- Boston Scientific Corporation
- Product code
- LTI
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P140008/S028 received
Application receipt date recorded by FDA.
P140008/S028 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P140008. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code LTI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Allurion Gastric Balloon SystemP250023/S002 | Allurion Technologies, Inc. | PMA supplement | Sep 23, 2026 | FDA |
Allurion Gastric Balloon SystemP250023/S001 | Allurion Technologies, Inc. | PMA supplement | Sep 9, 2026 | FDA |
| Allurion Technologies, Inc. | PMA approval | Feb 20, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 100 Boston Scientific Way, Marlboro, MA, 01752
Sources and methodology
- Original FDA record: P140008/S028
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

